A B S T R A C T This study describes two sensitive, rapid, relatively simple, competitive inhibition radioimmunoassays for detecting immune complex. 
I'25-monoclonal rheumatoid factor (mRF) binding to an insoluble substrate, IgG-Sepharose. The assays can be performed in 5 h utilizing 10 ,ul of serum. Heating of serum is not required and polyclonal rheumatoid factors do not interefere. With the two assays, a wide range of complexes of various size and complement fixing activity can be detected. The Clq test can detect complement fixing Ig complexes larger than 19S, while the mRF tests detect complexes of IgG as small as 8S irrespective of their complement fixing activity. Mouse, rabbit, and human aggregated IgG (agg IgG) can be detected in the Clq test, and human and rabbit agg IgG in the mRF test. As low as 4 ,ug/ml of isolated human agg IgG can be detected in the Clq test and 0.5 ,ug/ml in the rheumatoid factor test. Sensitivity is greater for mouse agg IgG. For pathologic sera which must be diluted to eliminate interfering factors, the sensitivity of the assay is approximately 10 times less. The Clq test showed marked inhibition by systemic lupus erythematosus sera with close correlation with CH50 levels and disease activity. The mRF test showed better correlation with rheumatoid arthritis sera. In addition, anionic macromolecules known to react with Clq and other Clq reactants that occur in pathologic sera such as the "low molecular weight" substances in systemic lupus erythematosus are also detected. These reactants are not detectable in the mRF test and can be eliminated in the Clq test by performing the test at higher ionic strength. The tests can be applied to the study of a variety of pathologic states where immune complexes appear to play a role.
INTRODUCTION
At present there continues to be a great need for sensitive quantitative tests for the detection of antigen-antibody complexes. The possible role of immune complexes in a variety of basic immune mechanisms is currently under intensive study (1) (2) (3) (4) and in addition immune complexes have been shown to have an important role in a wide variety of diseases (5) (6) (7) (8) (9) (10) (11) (12) . 1 Various techniques have been described for detecting immune complexes (13, 14) but none so far have achieved the sensitivity, quantitative capacity, and simplicity for wide application. A major approach to the detection of immune complexes has been the use of reagents which will react preferentially with complexed immunoglobulins but not monomeric immunoglobulins. Two such reagents are the Clq component of complement (15, 16) and monoclonal anti-IgG (monoclonal rheumatoid factor, mRF) (17) .2 These two reagents have been used for the detection of immune complexes in a variety of technical procedures, including more recently radioimmunoassays (18) (19) (20) (21) (22) (23) . Tests with either reagent have limitations (14) ; however, when radioimmunoassay methods utilizing both reagents are run in parallel, the system has the capability of detecting both complementfixing and noncomplement-fixing immune complexes over a wide range of molecular weights.
This approach has been taken in this study and two new radioimmunoassays are described, which present considerable improvement over the current methods.
METHODS

Reagents
Monoclonal anti-IgG. A mRF from a patient with Waldenstrom's macroglobulinemia was selected for specificity for aggregated IgG (agg IgG) as demonstrated in gel diffusion (Fig. 1) . A broad reactivity with variety of different heated gamma globulins was observed, suggesting no allotype specificity. The mRf was isolated by affinity chromatograph with a 5/35-cm IgG-p-azobenzamidoethyl Sepharose-6B column (Pharmacia Fine Chemicals, Inc., Piscataway, N. J.), prepared according to the method of Bing (24) . The protein was eluted with 2 M glycine-HCl, pH 2.8. The peak obtained was pooled, dialysed against phosphate-buffered saline, aliquoted, and stored at -70°C. Just before use the samples were thawed and centrifuged at 2,000 rpm for 10 min at 4°C.
Clq component of complement. Clq was isolated from fresh normal serum by precipitation with deoxyribonucleic acid (DNA, Worthington Biochemical Corp., Freehold, N. J.) (14) and further purified by chromatography in Sephadex G-200 column (Pharmacia Fine Chemicals, Inc.) and zone electrophoresis (25) . Purity of preparation was ascertained by radical immunodiffusion against anti-IgG, anti-IgM, and anti-IgA (Tri-Partigen Behring Diagnostics, American Hoechst Corp., Somerville, N. J.). There was less than 2% contamination with IgM and IgG. Just before use the samples were thawed and centrifuged at 2,000 rpm for 10 min at 4°C.
IgG-Sepharose. The procedure of Bing (24) (26) . Extent of aggregation of proteins was determined by density gradient ultracentrifugation analyses.
DNA preparations. To minimize contaminating singlestranded DNA (SDNA) in native DNA preparations (Worthington DNA), solutions were filtered through a 0.45-mm cellulose filter (Millipore Corp., Bedford, Mass.) which selectively binds SDNA. Denatured DNA (SDNA) was prepared by heating 0.5 mg/ml solution of DNA in boiling water for 15 min and immediately plunging the tube into ice water. DNAse treatment was performed as previously described (16) .
Soluble antigen-antibody complexes. Immune serum was obtained from a rabbit hyperimmunized with human serum albumin (ICN Nutritional Biochemicals Div., International Chemical & Nuclear Corp., Cleveland, Ohio). Soluble immune complexes were prepared as previously described (16) .
Radioiodination
Lactoperoxidase-catalyzed radioiodination was routinely conducted in isotonic veronal buffer, 0.01 M, pH 7.4, by a FIGURE 1 Gel diffusion plate showing precipitation of an isolated monoclonal anti-IgG (mRF) with agg IgG (1 mg/ml). Neither precipitation nor inhibition of the mRF-agg IgG line occur with monomeric IgG (3 mg/ml). modified method of Heusser et al. (27) 
RESULTS
Conditions for binding of 1125-Clq and I'25-mRF to IgG-Sepharaose. Binding of I125-Clq was studied as a function of composition and ionic strength (conductance) of buffers and temperature and time of incubation. Maximal binding ofI125-Clq to IgG-Sepharose was obtained at 40C after 1 h of incubation. Prolonging the period of incubation up to 24 h increased the binding by only 10%. The maximal binding ofI125-Clq to IgG-Sepharose was obtained with 0.075 M Tris-HCl, 0.01 M Na2H2-EDTA, pH 7.4, 1% BSA, conductance 7.0 m mho/cm, which is consistent with that previously reported (22) . It was necessary to add 1% BSA to the buffers to prevent nonspecific sticking of I'25-Clq to the tube.
A washing step was found to be essential to increase the specificity of the inhibition step of the assay. A high ionic strength buffer 0.4 M NaCl, 0.1 M Na2H2-EDTA, pH 7.4, conductance 45 m mho/cm, was selected to eliminate nonspecific bound Clq to IgGSepharose as well as other contaminating proteins since it is well known that at low ionic strength, proteins can be nonspecifically bound to an insoluble phase. The wash step considerably decreased the counts bound to the gel. Clq bound to IgGSepharose is known to be very stable under these conditions (24) but to confirm this, unlabeled Clq in higher concentrations was incubated with a proportional amount of IgG-Sepharose, and the gel was washed. Clq could not be detected in the washed supernates.
Binding of 1125-mRF was studied in the same way. I125-mRF binds better at higher temperatures than Clq. However, no significant difference was observed between 40 The inhibition by agg IgG in the presence of normal serum was tested by diluting different amounts of human agg IgG in normal serum diluted 1:20 for the Clq and 1:10 for the mRF. For the mRF test, agg IgG dissolved in normal serum showed the same level of inhibition as compared to agg IgG in buffer. However, for the Clq test, the amount of agg IgG necessary to produce 50% inhibition increases approximately 10 times, when utilizing agg IgG dissolved in normal serum. Dilution of normal serum greater than 1:100 did not produce any decrease in sensitivity.
To examine this phenomenon normal serum was treated in different ways before the addition of agg IgG. Treatments consisted of: (a) heating at 56°C for 30 min; (b) adding EDTA to a final concentration of 0.2 M; and (c) adding 0.01 M EDTA and antiClq, followed by centrifugation at 20,000 rpm for 20 min and filtration of the supernate through a 0.4-mm cellulose filter to specifically deplete Clq (Clq R reagent). The Reproducibility of the RIA and effect of heating and thawing. Decomplementation by heating at 56°C for 30 min was carried out in four normal and four known positive sera and the results in both tests compared to those of fresh sera. The inhibition increased in normal sera and was variable, higher or lower for the pathologic sera. The effect of heating normal serum was further studied by the following experiments: I125-Clq or I125-RF was added to normal serum or normal serum heated at 560 for 30 min and fractionated on a sucrose density gradient. In the unheated sera the Clq sedimented in its usual 11S location and the mRF just beyond the 19S marker (probably 22S). In the heated sera both the Clq and RF were found in the lower part of the gradient. Fig. 7 (25) (100) (100) FIGURE 9 Similar study as Fig. 8 The Clq test showed a higher incidence of positives and higher levels of positivity than the mRF assay in systemic lupus erythematosus (SLE) and juvenile rheumatoid arthritis (JRA) Fig. 10a . The mRF test detects only the larger inhibitor in these sera and not the low molecular weight substance that reacts with Clq. These low molecular weight substances which have been previously 996 A. Gabriel, Jr., and V. Agnello described in SLE (6) are similar to the low molecular weight substances found in the SLE-related syndrome (33) . A sucrose density gradient analysis of a serum from a patient with this syndrome is also shown in Fig. 10b . Only low molecular weight reactants are found in these sera, and as in the SLE sera, the reactant does not inhibit the mRF test. In the second study the positive SLE sera were also tested at higher ionic strength (conductance = 9 m mho/cm) in the Clq test. The number of positive results decreased from 68% to 48%. Under these conditions it can be shown by sucrose density gradient experiments that the low molecular weight reactants in sera from patients with SLE and the SLE-related syndrome do not inhibit Clq binding.
Among the sera from patients with JRA studied, five were positive in both tests, five were positive in only the Clq test. One serum was weakly positive in only the mRF test. In those positive in both tests the correlation of levels of positivity was again low. The findings are similar to those in SLE; however, the concentrations of inhibiting substances is considerably lower. Attempts at further characterization of these substances have not been made.
In contrast with the Clq assay, the mRF assay showed a higher incidence of positives among sera of patients with Rheumatoid Arthritis (RA) and malignant melanoma. Differences in both the number of positives and the level of positivity were found for RA sera but were not as marked as those described above for SLE sera in the Clq assay. Approximately 85% of the RA sera were positive in both tests. The correlation of the levels of positivity in two tests was low (r = 0.36). In the majority of positive sera the level of positivity was higher in the mRF test. Approximately 15% of the RA sera were positive in the mRF assay only. None were positive in only the Clq assay. The increased positivity of BA sera in the mRF test could possibly be due to interference from rheumatoid factors which are present in high incidence in this disease. In one assay reported utilizing rheumatoid factors for the detection of complexes, rheumatoid factors present in pathologic sera were found to markedly interfere (20) . However, in that study polyclonal rheumatoid factor was used as a reagent. In another assay utilizing a monoclonal rheumatoid factor reagent, no interference was detected by hightitered polyclonal rheumatoid factor (21) . In these studies there was no apparent interference of free rheumatoid factor present in RA sera. A group of RA sera was studied as shown in Table I . There was no correlation between positivity in the mRF assay and serum rheumatoid factor titers (r = 0.14) or serum IgG concentrations (r = 0.20). In the same study there was also no correlation between positivity in the Clq assay, and serum rheumatoid factor titer (r = 0.00) or serum IgG concentrations (r = 0.10). The effect of free rheumatoid factors in these sera was further studied by isolating the rheumatoid factors from three of the sera strongly positive in the mRF assay. The isolated rheumatoid factors in the same concentration found in the starting sera did not inhibit the binding of the labeled mRF. Additional evidence of this type is shown in Fig. 11 . A rheumatoid synovial fluid strongly positive for both RF and immune complexes was fractioned by sucrose density gradient. Complexes could be demonstrated in the bottom of the gradient by both the RF and Clq tests. RF present in the 19S region did not inhibit either test. From the above studies it does not appear that free rheumatoid factors in RA sera are responsible for the increased reaction of these sera in the mRF assay compared with the Clq assay. A more likely possibility was illustrated by sucrose density gradient analysis of RA sera. In some patients reactants with both mRF and Clq were observed in the region greater than 19S but in addition substances between the 7S and 19S which inhibited only the mRF assay could be demonstrated (Fig. lOd) . This finding is consistent with the intermediate complexes previously reported (17 (Fig. lOc) .
A greater incidence of positivity in the mRF assay compared to the Clq assay was also seen in the studies on sera from patients with malignant melanoma although only a few sera were tested. The In addition, heating of serum specimens as is necessary in a number of other assays is not required. Heating serum specimens as shown in these studies causes aggregation of immunoglobulins and may also destroy thermolabile antigens that possibly are present in immune complexes in unknown pathologic sera. The use of a mRF with high avidity for complex IgG minimizes the interference by monomeric IgG and polyclonal rheumatoid factors. However, the high IgG levels in serum still present an interference problem which is circumvented by using a 1:10 dilution of test sera. Sensitivity of the assay is proportionately decreased by the dilution step, but in spite of this, on the basis of the limited comparative data currently available, the test with mRF is more sensitive than any assay thus far well characterized (14) .
Endogenous Clq interferes with the detection of complexes of IgG added to normal serum. The techniques used by others, heating (18, 22) or EDTA (35) (33) and in denque (22) . As shown, the Clq test can be done at conditions which eliminate the reaction of anionic substances but the sensitivity for detecting complexes of IgG is significantly reduced.
The reaction of SDNA with Clq is of considerable interest and may be of some importance in the immunopathology of SLE (36) (37) (38) . In contrast to NDNA and the other anionic substances tested, SDNA reacts with Clq at higher ionic strength. This is consistent with previous studies which have shown that SDNA can activate complement under physiologic conditions whereas native DNA does not (39) . Under the conditions which the Clq assay is performed in this study as well as in other studies, (e.g., the Clq deviation test), the inhibition of SDNA is considerably greater than that for aggregated gamma globulin on an equivalent weight basis. In studying SLE patients then, with the Clq binding test, enhanced inhibition could occur with the presence of SDNA antigen alone or to complexes containing SDNA antigen. There is yet no direct evidence for this, but the possibility is not unlikely and is under study. In addition, complexes of SDNA antigen and NDNA antibody could exist in the presence of excess NDNA antibody and provide a possible explanation for the findings demonstrated in Fig. 12 .
Differences in the sizes of complexes detected is a characteristic of the two assays which can provide useful information when the tests are run parallel. This is most clearly demonstrated in evaluating certain pathologic specimens. In some SLE sera both high molecular weight and low molecular weight substances that are reactive with Clq have been detected. In sucrose density gradient analysis it can be shown that the high molecular weight substances react with both Clq and monoclonal rheumatoid factor as would be expected for complexes of gamma globulin whereas low molecular weight substances react with only Clq. Knowing that Clq reacts with certain anionic substances and does not react with complexes of gamma globulin below 19S in size, this finding would be most consistent with the presence of an anionic substance in the SLE sera that reacts with Clq but not monoclonal rheumatoid factor. Similar low molecular weight substances have been recorded in a group of patients who have an SLE-like syndrome (33) In interpreting the results of these tests, it must be kept in mind that neither assay differentiates reaction due to immune complexes from those due to nonspecifically aggregated Ig such as might occur in vivo with physical alteration of Ig or in vitro. The precautions described for the use of these tests are designed to minimize the latter problem. For definitive evidence that immune complexes are responsible for the inhibition reaction, both antigen and antibody must be identified in reactive substance. A major problem in attempting such characterization with previous techniques has been the marked dilutions that occur with isolation procedures. The increased sensitivity afforded by these new assays may possibly eliminate this problem.
